Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.
Takako Eguchi NakajimaShigenori KadowakiKeiko MinashiTomohiro NishinaTakeharu YamanakaYuichiro HayashiNaoki IzawaKei MuroShuichi HironakaTakeshi KajiwaraYutaka KawakamiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Nivolumab with paclitaxel plus ramucirumab demonstrated promising antitumor activity with manageable toxicities as second-line treatment for AGC.